Source study found
Story checked
Molecular imaging demonstrates promise for predicting complete pathologic response in HER2-positive breast cancer (opens in a new tab)
medicalxpress.com · 2026-10-16
Short answer
MixedMixed.
One claim goes further than the study. 2 other points were not covered by the paper.
- 2 supported
- 1 overstated
- 2 not covered
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Molecular imaging demonstrates promise for predicting complete pathologic response in HER2-positive breast cancer
medicalxpress.com · 2026-10-16
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Mixed
One claim overstates the study. Two of five check out. Two claims the study doesn't address.
- 2 supported
- 1 overstated
- 2 not covered
The source study
68Ga-HER2 PET/CT for Predicting Pathologic Response to Neoadjuvant Therapy at Early Treatment and Preoperative Stages in HER2-Positive Breast Cancer: A Prospective Study.
Evidence layer
Claim by claim
Each claim gets a verdict. Expand it to see the evidence directly below.
Reading mode
Scan verdicts. Open evidence only when needed.
Browse by verdict
5 claims in this storyShowing all 5 claimsChoose a verdict to focus the list.
Claim 1 of 5OverstatedAccording to new research published in the October issue of The Journal of Nuclear Medicine, ⁶⁸Ga-HER2 PET/CT can detect changes in HER2-positive breast cancer after only two cycles of neoadjuvant treatment, giving physicians information that could support earlier discussions about subsequent treatment and surgical planning.View evidenceHide evidence
Why this verdict
The paper profile supports that PET2 after two cycles measured SUVmax changes and that PET2 thresholds were associated with/stratified pCR likelihood. However, the claim goes beyond the abstract-level evidence by saying the information could support subsequent treatment and surgical planning; the supplied profile does not show that PET/CT-guided discussions, treatment changes, or surgical planning were tested or improved.
Study evidence
Baseline 68Ga‑HER2 PET/CT tumor SUVmax (PET1) did not differ between patients with subsequent pCR and non‑pCR (3.76 ± 1.97 vs 3.79 ± 2.71; P = 0.349).difference in means; P = 0.349
“In total, 45 patients with newly diagnosed HER2-positive breast cancer eligible for NAT were enrolled.”
Study evidence
Application of PET2 thresholds for SUVmax (≤1.15) and ΔSUVmax (≥61%) identified a therapy-sensitive subgroup with PPV for pCR of 85% and NPV of approximately 60%, representing an ~15% absolute increase in pCR likelihood compared with the nonsensitive subgroup.PPV 85%; NPV ≈ 60%; absolute increase in pCR probability ≈ 15%
“Application of the PET2 cutoff thresholds for SUVmax and ΔSUVmax identified a therapy-sensitive subgroup, which had a positive predictive value for pCR of 85%”
Claim 2 of 5Not coveredPatients whose primary tumor tracer uptake decreased by at least 61% after the second treatment cycle had an 85% rate of pathologic complete response, compared with 38% among patients whose uptake decreased by less than 61%.View evidenceHide evidence
As stated85% vs 38%
Why this verdict
The abstract-profile supports a PET2 ΔSUVmax ≥61% threshold and reports a therapy-sensitive subgroup with PPV for pCR of 85%. But it does not provide the exact 85% versus 38% comparison as stated, nor does it clearly establish that the 85% figure applies solely to the ≥61% uptake-decrease split rather than to application of PET2 SUVmax and ΔSUVmax thresholds. Subgroup counts and full contingency data are not available at abstract depth.
Study evidence
Baseline 68Ga‑HER2 PET/CT tumor SUVmax (PET1) did not differ between patients with subsequent pCR and non‑pCR (3.76 ± 1.97 vs 3.79 ± 2.71; P = 0.349).difference in means; P = 0.349
“In total, 45 patients with newly diagnosed HER2-positive breast cancer eligible for NAT were enrolled.”
Study evidence
Application of PET2 thresholds for SUVmax (≤1.15) and ΔSUVmax (≥61%) identified a therapy-sensitive subgroup with PPV for pCR of 85% and NPV of approximately 60%, representing an ~15% absolute increase in pCR likelihood compared with the nonsensitive subgroup.PPV 85%; NPV ≈ 60%; absolute increase in pCR probability ≈ 15%
“Application of the PET2 cutoff thresholds for SUVmax and ΔSUVmax identified a therapy-sensitive subgroup, which had a positive predictive value for pCR of 85%”
Claim 3 of 5Not coveredThe authors said the findings are preliminary and that the study was limited by its small sample size, single-center design, and variation in neoadjuvant treatment regimens; they also noted the study did not test whether changing treatment based on PET/CT findings improves outcomes.View evidenceHide evidence
Why this verdict
Several caveats are supported by the profile: small cohort, heterogeneous systemic regimens, observational diagnostic/prognostic design, no external validation, and no testing of PET-guided treatment changes. However, the supplied abstract-profile does not identify the study as single-center or verify the full 'authors said' formulation, so the complete claim is not fully verifiable at this evidence depth.
Study evidence
Baseline 68Ga‑HER2 PET/CT tumor SUVmax (PET1) did not differ between patients with subsequent pCR and non‑pCR (3.76 ± 1.97 vs 3.79 ± 2.71; P = 0.349).difference in means; P = 0.349
“In total, 45 patients with newly diagnosed HER2-positive breast cancer eligible for NAT were enrolled.”
Study evidence
Application of PET2 thresholds for SUVmax (≤1.15) and ΔSUVmax (≥61%) identified a therapy-sensitive subgroup with PPV for pCR of 85% and NPV of approximately 60%, representing an ~15% absolute increase in pCR likelihood compared with the nonsensitive subgroup.PPV 85%; NPV ≈ 60%; absolute increase in pCR probability ≈ 15%
“Application of the PET2 cutoff thresholds for SUVmax and ΔSUVmax identified a therapy-sensitive subgroup, which had a positive predictive value for pCR of 85%”
Claim 4 of 5SupportedMolecular imaging with ⁶⁸Ga-HER2 PET/CT may provide an early, targeted measure of how well treatment is working in patients with HER2-positive breast cancer.View evidenceHide evidence
Why this verdict
The abstract-profile supports a hedged, associational claim that serial 68Ga-HER2 PET/CT, especially early on-treatment PET2 measures after cycle 2, was associated with later pathologic complete response in HER2-positive breast cancer. The story frames this as 'may provide' an early measure rather than as proven outcome-improving clinical management.
Study evidence
Baseline 68Ga‑HER2 PET/CT tumor SUVmax (PET1) did not differ between patients with subsequent pCR and non‑pCR (3.76 ± 1.97 vs 3.79 ± 2.71; P = 0.349).difference in means; P = 0.349
“In total, 45 patients with newly diagnosed HER2-positive breast cancer eligible for NAT were enrolled.”
Claim 5 of 5SupportedIn the study, a baseline scan did not distinguish patients who would or would not achieve a pathologic complete response, but after two cycles a substantial reduction in tracer uptake in the primary breast tumor was associated with a pathologic response at surgery.View evidenceHide evidence
As stated≥61% decrease in uptake
Why this verdict
The profile directly reports that baseline PET1 SUVmax did not significantly differ between pCR and non-pCR groups, while PET2 SUVmax and PET2 percent change were associated with pCR. The ≥61% PET2 ΔSUVmax cutoff is specifically reported in the abstract-profile.
Study evidence
Baseline 68Ga‑HER2 PET/CT tumor SUVmax (PET1) did not differ between patients with subsequent pCR and non‑pCR (3.76 ± 1.97 vs 3.79 ± 2.71; P = 0.349).difference in means; P = 0.349
“In total, 45 patients with newly diagnosed HER2-positive breast cancer eligible for NAT were enrolled.”
Context layer
What the story left out
Important study details the story did not include.
The paper also reports preoperative PET3 findings, including PET3 SUVmax and PET3 ΔSUVmax ≥72% thresholds with similar moderate AUCs.
The story focuses on baseline and PET2 early-treatment imaging and does not mention the PET3/preoperative results.
From prospective cohort diagnostic/prognostic
The abstract-profile notes an internal inconsistency in reported counts: total N is 45, while pCR and non-pCR counts as presented sum to 44.
The story does not mention this abstract-level inconsistency, which may matter when interpreting precise percentages and predictive values.
From prospective cohort diagnostic/prognostic
4 things the story did carry across
- Prospective observational cohort of HER2-positive breast cancer patients undergoing serial 68Ga-HER2 PET/CT at baseline, after cycle 2, and before surgery, with surgical pCR as the endpoint.
- Baseline PET1 primary tumor SUVmax did not distinguish later pCR from non-pCR.
- Early on-treatment PET2 measures were associated with pCR: lower PET2 SUVmax in pCR patients and a PET2 ΔSUVmax threshold of ≥61% with AUC about 0.742.
- The study was diagnostic/prognostic and observational; it did not test whether changing treatment based on PET/CT results improves patient outcomes.
Study layer
Study at a glance
Scan the study first. Expand only the parts you want to inspect.
Pieces of work
2
Evidence read
study summary
Lead result
human in vivo
1Lead resulthuman in vivoEvaluate whether 68Ga-HER2 PET/CT uptake (SUVmax) and its early/on-treatment changes predict pathologic complete response (pCR) to neoadjuvant anti-HER2 therapy in newly diagnosed HER2-positive breast cancer, including derivation of PET2/PET3 cutoffs and predictive performance.prospective cohort diagnostic/prognosticExpandCollapse
In plain English
Prospective cohort study (n=45) evaluated whether serial 68Ga-HER2 PET/CT SUVmax and percent change (ΔSUVmax) at early on‑treatment (after cycle 2, PET2) and preoperative (PET3) timepoints predict pathologic complete response (pCR) to neoadjuvant anti‑HER2 therapy in newly diagnosed HER2‑positive breast cancer. Early/post‑treatment decreases in tumor SUVmax (PET2, PET3) and specified ROC‑derived cutoffs (SUVmax and ΔSUVmax) were associated with pCR and yielded AUCs ~0.74; baseline SUVmax (PET1) did not distinguish pCR vs non‑pCR.
Key findings
- Baseline 68Ga‑HER2 PET/CT tumor SUVmax (PET1) did not differ between patients with subsequent pCR and non‑pCR (3.76 ± 1.97 vs 3.79 ± 2.71; P = 0.349).difference in means; P = 0.349
- Early on‑treatment (PET2, after cycle 2) tumor SUVmax was significantly lower in patients who achieved pCR versus non‑pCR (0.45 ± 0.71 vs 2.01 ± 2.36; P = 0.008).difference in means; P = 0.008
“In total, 45 patients with newly diagnosed HER2-positive breast cancer eligible for NAT were enrolled.”
What this piece can’t prove
- Small cohort size reported (n = 45), which may limit precision of AUC and predictive value estimates.
- Heterogeneity in systemic regimens (trastuzumab + pertuzumab or pyrotinib‑based) indicated in abstract; subgroup effects not reported in abstract.
- Abstract does not report confidence intervals, sensitivity/specificity, or detailed ROC operating points, limiting assessment of clinical utility.
2 further details could not be confirmed from the summary.
2human in vivoExplore whether applying PET2-derived thresholds can stratify a therapy-sensitive subgroup with higher PPV for pCR (clinical enrichment/stratification utility).Prospective cohort stratification analysisExpandCollapse
In plain English
In the prospective cohort, applying PET2-derived thresholds (SUVmax ≤ 1.15 and/or ΔSUVmax ≥ 61%) to classify patients identified a "therapy-sensitive" subgroup with a positive predictive value (PPV) for pathologic complete response (pCR) of 85% and a negative predictive value (NPV) of approximately 60%, corresponding to an absolute ~15% higher likelihood of pCR versus the nonsensitive subgroup. Thresholds and predictive values were reported from the study cohort.
Key findings
- Application of PET2 thresholds for SUVmax (≤1.15) and ΔSUVmax (≥61%) identified a therapy-sensitive subgroup with PPV for pCR of 85% and NPV of approximately 60%, representing an ~15% absolute increase in pCR likelihood compared with the nonsensitive subgroup.PPV 85%; NPV ≈ 60%; absolute increase in pCR probability ≈ 15%
“Application of the PET2 cutoff thresholds for SUVmax and ΔSUVmax identified a therapy-sensitive subgroup, which had a positive predictive value for pCR of 85%”
What this piece can’t prove
- Relatively small overall sample size reported (N = 45), which may limit precision of PPV/NPV estimates.
2 further details could not be confirmed from the summary.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
68Ga-HER2 PET/CT for Predicting Pathologic Response to Neoadjuvant Therapy at Early Treatment and Preoperative Stages in HER2-Positive Breast Cancer: A Prospective Study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
Why this one
Near certain
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
PubMed, Europe PMC, Crossref · 15 candidate papers
68Ga-HER2 PET/CT for Predicting Pathologic Response to Neoadjuvant Therapy at Early Treatment and Preoperative Stages in HER2-Positive Breast Cancer: A Prospective Study.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine · 2026 · PubMed, Europe PMC
Towards integration of 64Cu-DOTA-Trasztusumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2+ breast cancer
Crossref
Ternary classification prediction and heterogeneity quantification for HER2-Zero, -low, and -positive in breast cancer using HER2-targeted PET/CT imaging.
European Journal of Nuclear Medicine and Molecular Imaging · 2026 · PubMed
Abstract PS1-06-30: Predicting pathological response to neoadjuvant therapy in HER2-positive breast cancer by using 68Ga-HER2 PET/CT: a prospective study
Clinical Cancer Research · 2026 · Crossref
[68Ga]Ga-NOTA-T4 PET/CT imaging of TROP2 expression in patients with HER2-negative breast cancer.
2026 · Europe PMC
Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial.
PLoS Medicine · 2025 · PubMed
And 9 more candidates considered.